CIDP Efficacy and Safety
Proven in the largest trial of CIDP and further evaluated in an extension study
EAN/PNS guideline recommends tailoring SCIg dose according to individual treatment response19
CIDP and the PATH study
Watch a summary of Dr. Jeffrey A. Allen's talk from the 2018 AANEM conference, where he discusses the PATH trial.
Want to know more about Hizentra? See answers to many prescribers' frequently asked questions.Frequently asked questions about CIDP
Create personalized treatment plans to meet your patients' clinical needs and personal preferences.See why Hizentra may be right for your patients